Celsion CEO Michael Tardugno - An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
This article was originally published in The Pink Sheet Daily
Executive Summary
Tardugno speaks with the DAILY about the regulatory timeline and commercialization plans for ThermoDox, including plans to market the heat-activated liposomal-delivery doxorubicin in Asia.
You may also be interested in...
Celsion CEO Michael Tardugno – An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
Tardugno speaks with the DAILY about his company’s transition from a device firm to an oncologic development company and about its proprietary technology.
Bayer/Onyx’s Nexavar Gets Liver Cancer Indication
Sorafenib becomes first systemic drug therapy approved for unresectable HCC.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”